Artelo Biosciences, Inc. ARTL
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Artelo Biosciences, Inc. (ARTL) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -101%.
About Artelo Biosciences
Artelo Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$13M | -$10M | -$9M | -$10M | -$9M | -$5M | -$2M | -$2M | -$234889 | -$29690 |
| Free cash flow | -$9M | -$8M | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-12.52 | $-18.30 | $-18.85 | — | — | $-7.56 | $-8.76 | $-11.04 | $-0.18 | $0.00 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | -269.7% | -66.6% | -41.8% | -27.3% | -95.5% | -46.4% | — | -33.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Artelo Biosciences pay a dividend?
Not currently.
Is Artelo Biosciences a good stock to buy?
We do not give buy or sell advice. Artelo Biosciences scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.